The Future of Neurodegenerative Disease Begins with Earlier Detection
Kivara Neurosciences is developing next-generation diagnostic technologies designed to identify neurodegenerative disease risk before irreversible damage occurs — enabling earlier intervention, better patient outcomes, and more effective therapeutic development.
By the Time Symptoms Appear, the Damage Is Already Done
Neurodegenerative diseases progress silently for years — sometimes decades — before clinical symptoms emerge. By the time patients seek care, substantial neurological damage has often already occurred, narrowing the window for meaningful intervention.
Healthcare Is Transitioning from Reactive Care to Predictive Medicine
The most valuable companies in medicine over the next two decades will be those that enable identification, stratification, and monitoring of disease — not those that simply react to it.
Reactive Care
- — Diagnose disease after symptoms appear
- — Treat symptoms, not biology
- — One-size-fits-all therapeutics
- — Limited longitudinal monitoring
Predictive Medicine
- → Identify disease risk before symptoms occur
- → Monitor biological progression in real time
- → Guide targeted therapeutic intervention
- → Track treatment effectiveness longitudinally
Diagnostics are the critical infrastructure of this transformation — the layer that makes everything else possible.
A Multi-Billion Dollar Opportunity
Three converging markets — biomarkers, Alzheimer's diagnostics, and broader neurodegenerative diagnostics — are growing rapidly as the global burden of disease accelerates and disease-modifying therapies require better patient identification.
Neurological Biomarkers Market
Alzheimer's Diagnostics Market
Neurodegenerative Diagnostics
Diagnostics Capture Value Across the Entire Patient Journey
Breakthrough Therapies Require Better Diagnostics
Billions of dollars are now flowing into neurodegenerative therapeutics. But these therapies only work when the right patients are identified at the right time — creating direct, structural demand for diagnostic platforms like Kivara.
The Companion Diagnostic Era
More Than a Single Test
Kivara is being built as a platform — one core technology, many indications. Each future application compounds the value of the underlying science.
Platform
Converging Trends Are Creating a Historic Opportunity
Aging Global Population
1B+ people over 60 by 2030
Healthcare Spending Growth
$10T+ global market
Precision Medicine Adoption
Standard of care shift
Biomarker Validation
Plasma & digital biomarkers maturing
AI-Enabled Diagnostics
Pattern recognition at scale
Disease-Modifying Therapies
Approved & rapidly expanding
Demand for Early Intervention
Patients, payors, and providers aligned
Why Kivara
Massive Market Opportunity
Multi-billion dollar diagnostic and biomarker markets growing at double-digit CAGR.
Prevention-Focused Healthcare Shift
Aligned with the global pivot from reactive treatment to predictive medicine.
Scalable Diagnostic Platform
One core technology engineered to support many future applications and indications.
Multiple Future Indications
Alzheimer's, Parkinson's, FTD, Lewy Body, and beyond — each a multi-billion dollar market.
Companion Diagnostic Potential
Positioned to power the next wave of disease-modifying therapeutics.
Strategic Acquisition Potential
Diagnostic platforms are among the most strategically valued assets in precision medicine.
Building the Future Standard for Neurodegenerative Disease Detection
Kivara Neurosciences is pursuing a future where neurodegenerative diseases are identified years before symptoms emerge — enabling earlier intervention, accelerating therapeutic innovation, and transforming the standard of care for millions of patients worldwide.